Results 21 to 30 of about 23,603 (217)
Long-acting reversible contraception use among residents in obstetrics/gynecology training programs [PDF]
, 2017 Background: The objective of the study was to estimate the personal usage of long-acting reversible contraception (LARC) among obstetrics and gynecology (Ob/Gyn) residents in the United States and compare usage between programs with and without a Ryan
Maddipati, Ragini +4 more
core +2 more sources
Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. [PDF]
, 2020 BackgroundThe levonorgestrel 52-mg intrauterine system has proven efficacy for heavy menstrual bleeding treatment in clinical trials, but few data exist to demonstrate how rapidly the effects occur and the effects in women with self-reported heavy ...
Chen, Beatrice A +5 more
core
Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling
Frontiers in Endocrinology, 2021 There is a steady global rise in the use of progestin subdermal implants, where use has increased by more than 20 times in the past two decades. BC risk has been reported with the older progestin only methods such as oral pills, injectables, and ...
Ghada Mohammed +6 more
doaj +1 more source
PharmaceuticsBackground: Levonorgestrel implant is a highly effective hormonal contraceptive, but its efficacy may be compromised when used with cytochrome enzyme inducers such as efavirenz. The primary aim of this study was to evaluate methods of mitigating the drug
Lilian W. Adeojo +2 more
doaj +1 more source
PLoS ONE, 2015 ObjectiveTo evaluate the cost-effectiveness of ulipristal acetate and levonorgestrel in minors in France, and analyze whether it is worthwhile to provide ulipristal acetate to minors free of charge.MethodsThe cost-effectiveness of two emergency ...
Ramona Schmid
doaj +1 more source
Indonesian Journal of Obstetrics and Gynecology, 2014 Objective: To determine the comparison of body mass index (BMI) among acceptors of injectable depot medroxyprogesterone acetate (DMPA) with levonorgestrel implant acceptors for 1 year and comparison of lipid profiles between depot medroxyprogesterone ...
Irwan Daido +2 more
doaj +1 more source
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. [PDF]
, 2017 IntroductionPreventing unintended pregnancies is important among all women, including those living with HIV. Increasing numbers of women, including HIV-positive women, choose progestin-containing subdermal implants, which are one of the most effective ...
Cohen, Craig R +5 more
core +2 more sources
Регуляторные исследования и экспертиза лекарственных средств, 2018 The article compares test methods and levels of requirements laid out in the world’s leading pharmacopoeias and in manufacturers’ specifications with regard to the quality of levonorgestrel and ethinyl estradiol containing medicinal products used as oral
V. I. Seredenko +4 more
doaj +1 more source
Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: An economic evaluation alongside a randomised controlled trial [PDF]
, 2014 Objective: To undertake an economic evaluation alongside the largest randomised controlled trial comparing Levonorgestrel-releasing intrauterine device ('LNG-IUS') and usual medical treatment for women with menorrhagia in primary care; and compare the ...
A Stewart +23 more
core +5 more sources
Reproductive Medicine and Biology, 2021 Purpose We aimed to evaluate the efficacy and safety of 28‐day Cyclic and 84‐day Extended regimens of NPC‐16 (ethinylestradiol 0.02 mg plus levonorgestrel 0.09 mg) in patients with dysmenorrhea.
Tasuku Harada, Mikio Momoeda
doaj +1 more source